Matthew L. Sherman - 12 Dec 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
EVP & Chief Medical Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
12 Dec 2023
Net transactions value
-$42,905
Form type
4
Filing time
14 Dec 2023, 16:05:07 UTC
Previous filing
31 Oct 2023
Next filing
18 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award +8,244 +9.1% 99,306 12 Dec 2023 Direct F1, F2
transaction DCPH Common Stock Sale $42,905 -2,792 -2.8% $15.37 96,514 13 Dec 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 8,244 RSUs.
F2 Includes 434 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2023.
F3 This sale was to cover tax liabilities in the vesting of RSUs.